Preferences help
enabled [disable] Abstract
Number of results
2020 | 3 | 1 | 53-59
Article title

How to deal with patients with atrial fibrillation during the COVID-19 epidemic?

Title variants
Languages of publication
Patients with atrial fibrillation (AF) due to old age and comorbidities are at a higher risk of SARS-CoV-2 infection. These patients should protect themselves by limiting contact with other people to an absolute minimum and they should be educated about hygiene, including careful hand washing. In general, the principles of antiarrhythmic drug treatment of quarantined, infected and asymptomatic individuals remain unchanged. In the hospital setting it is important to remember about possible interactions between antibiotics, anticoagulants, antiarrhythmic, antiviral and antimalarial drugs. The current pandemic also led to limitations regarding the implantation and control of implantable devices to an absolute minimum.
Physical description
  • Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet [Internet]. 2020 Feb;395(10223):497–506. Available from:
  • Wu F, Zhao S, Yu B, Chen Y-M, Wang W, Song Z-G, et al. A new coronavirus associated with human respiratory disease in China. Nature [Internet]. 2020 Mar 3;579(7798):265–9. Available from:
  • Report of the who-china joint mission on coronavirus disease 2019 (covid-19) [Internet]. 2020. Available from:
  • World Health Organization. Q&A on coronaviruses (COVID-19) [Internet]. 2020 [cited 2020 Apr 14]. Available from:
  • Wujtewicz M, Dylczyk-Sommer A, Aszkiełowicz A, Zdanowski S, Piwowarczyk S, Owczuk R. COVID-19 – what should anaethesiologists and intensivists know about it? Anaesthesiol Intensive Ther [Internet]. 2020;52(1):34–41. Available from:
  • Hoffmann M, Kleine-Weber H, Schroeder S, Krüger N, Herrler T, Erichsen S, et al. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell. 2020 Mar 5;[in press].
  • Zhang H, Penninger JM, Li Y, Zhong N, Slutsky AS. Angiotensin-converting enzyme 2 (ACE2) as a SARS-CoV-2 receptor: molecular mechanisms and potential therapeutic target. Intensive Care Med [Internet]. 2020 Apr 3;46(4):586–90. Available from:
  • Wu Z, McGoogan JM. Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China. JAMA [Internet]. 2020 Apr 7;323(13):1239. Available from:
  • Yang J, Zheng Y, Gou X, Pu K, Chen Z, Guo Q, et al. Prevalence of comorbidities in the novel Wuhan coronavirus (COVID-19) infection: a systematic review and meta-analysis. Int J Infect Dis. 2020 Mar;[in press].
  • Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus–Infected Pneumonia in Wuhan, China. JAMA [Internet]. 2020 Mar 17;323(11):1061. Available from:
  • Zheng Y-Y, Ma Y-T, Zhang J-Y, Xie X. COVID-19 and the cardiovascular system. Nat Rev Cardiol [Internet]. 2020 Mar 5; Available from:
  • Clerkin KJ, Fried JA, Raikhelkar J, Sayer G, Griffin JM, Masoumi A, et al. Coronavirus Disease 2019 (COVID-19) and Cardiovascular Disease. Circulation [Internet]. 2020 Mar 21;CIRCULATIONAHA.120.046941. Available from:
  • Kumar P, Gordon LA, Brooks KM, George JM, Kellogg A, McManus M, et al. Differential Influence of the Antiretroviral Pharmacokinetic Enhancers Ritonavir and Cobicistat on Intestinal P-Glycoprotein Transport and the Pharmacokinetic/Pharmacodynamic Disposition of Dabigatran. Antimicrob Agents Chemother [Internet]. 2017 Nov 1;61(11):e01201-17. Available from:
  • Pradaxa. Summary of Product Characteristics. European Medicines Agency [Internet]. [cited 2020 Apr 14]. Available from:
  • Steffel J, Verhamme P, Potpara TS, Albaladejo P, Antz M, Desteghe L, et al. The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. Eur Heart J [Internet]. 2018;39(16):1330–93. Available from:
  • RoActemra. Summary of Product Characteristics. European Medicines Agency [Internet]. [cited 2020 Apr 14]. Available from:
  • Interactions with Experimental COVID-19 Therapies. The Liverpool Drug Interaction Group (University of Liverpool, UK), University Hospital of Basel (Switzerland) and Radboud UMC (Netherlands). [Internet]. [cited 2020 Apr 14]. Available from:
  • Azithromycin. Summary of Product Characteristics [Internet]. [cited 2020 Apr 14]. Available from:
  • Komunikat Sekcji Rytmu Serca Polskiego Towarzystwa Kardiologicznego dotyczący trybu i sposobu wykonywania zabiegów z zakresu elektroterapii lub elektrofizjologii serca w okresie epidemii COVID-19. [Internet]. [cited 2020 Apr 14]. Available from:
  • Komunikat Sekcji Rytmu Serca Polskiego Towarzystwa Kardiologicznego dotyczący trybu i sposobu przeprowadzania kontroli Elektronicznych Urządzeń Wszczepialnych (CIED) w okresie epidemii COVID-19 [Internet]. [cited 2020 Apr 14]. Available from:
Document Type
Publication order reference
YADDA identifier
JavaScript is turned off in your web browser. Turn it on to take full advantage of this site, then refresh the page.